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To identify genetic factors contributing to type 2 diabetes (T2D), we performed large-scale meta-analyses by using a custom ~50,000 SNP
genotyping array (the ITMAT-Broad-CARe array) with ~2000 candidate genes in 39 multiethnic population-based studies, case-control
studies, and clinical trials totaling 17,418 cases and 70,298 controls. First, meta-analysis of 25 studies comprising 14,073 cases and
57,489 controls of European descent confirmed eight established T2D loci at genome-wide significance. In silico follow-up analysis
of putative association signals found in independent genome-wide association studies (including 8,130 cases and 38,987 controls) per-
formed by the DIAGRAM consortium identified a T2D locus at genome-wide significance (GATAD2A/CILP2/PBX4; p ¼ 5.7 3 109) and
two loci exceeding study-wide significance (SREBF1, and TH/INS; p < 2.4 3 106). Second, meta-analyses of 1,986 cases and 7,695
controls from eight African-American studies identified study-wide-significant (p ¼ 2.4 3 107) variants in HMGA2 and replicated vari-
ants in TCF7L2 (p ¼ 5.1 3 1015). Third, conditional analysis revealed multiple known and novel independent signals within five T2D-
associated genes in samples of European ancestry and withinHMGA2 in African-American samples. Fourth, a multiethnic meta-analysis
of all 39 studies identified T2D-associated variants in BCL2 (p ¼ 2.1 3 108). Finally, a composite genetic score of SNPs from new and
established T2D signals was significantly associated with increased risk of diabetes in African-American, Hispanic, and Asian popula-
tions. In summary, large-scale meta-analysis involving a dense gene-centric approach has uncovered additional loci and variants that
contribute to T2D risk and suggests substantial overlap of T2D association signals across multiple ethnic groups.Introduction
Type 2 Diabetes (T2D [MIM 125853]) is a complex disease
caused by multiple genetic and environmental factors;
heritability is estimated at 22%–73% from twin and
family studies.1–5 The age-adjusted prevalence of T2D in
adults has recently been estimated at 7.6% in European
Americans, 14.9% in non-Hispanic African Americans,
4.3%–8.2% in Asian Americans, and 10.9%–15.6% in
Hispanics.6–9 Researchers have identified more than 40
T2D-associated genetic loci, but these loci have been re-
vealed primarily on the basis of studies of individuals of
European ancestry. Candidate-gene association studies
discovered association between T2D andmissense variants
in PPARG (MIM 601487) and KCNJ11 (MIM 600937),
which are targets for antidiabetic medications, and
implicated common genetic variants responsible for
Mendelian forms of diabetes in T2D (e.g., such variants
include those in the Wolfram-syndrome-associated locus
WFS1 [MIM 606201], those in HNF1A [MIM 142410]
and HNF4A [MIM 600281], and those in genes involved
in maturity-onset diabetes of the young [MODY (MIM
125851)]10–15). Association testing near a linkage peak
identified common variants in TCF7L2 (MIM 602228),
which remains the strongest signal for T2D and replicates
robustly across many,16 but not all, ethnic groups.17 Early
genome-wide association studies (GWASs) for T2D18–22
and fasting glucose23 successfully identified multiple loci.
Recent meta-analyses of GWASs of T2D24 and glycemic
quantitative traits25 have dramatically increased the
number of genome-wide-significant T2D-associated loci
in European populations; most of these variants act
through defects in beta-cell function rather than insulin
action. Together, variants known to be associated with
T2D explain ~10% of the genetic variance,24,26 indicating
that additional loci and independent signals in established
loci are likely to contribute to disease risk.
Genetic contributors to T2D are less well understood
in non-European populations. One novel locus (KCNQ1
[MIM 607542]) was identified on the basis of a GWAS
in a Japanese population27,28 and has subsequently
been shown to harbor independent alleles in individ-
uals of European descent.24 More recently, GWASs in412 The American Journal of Human Genetics 90, 410–425, March 9Chinese,29,30 Japanese,31 and South Asian populations32
describe additional T2D loci surpassing genome-wide
significance. To date, T2D GWASs in African-Americans
have been underpowered to detect novel loci.33
An important first step toward understanding genetic
risk across populations is to establish whether known T2D
association signals span ethnicities or are population
specific. Consistent association of T2D risk variants discov-
ered in Europeans was reported in a multiethnic case-
control study of five US populations,34 in studies of
Chinese,30 Japanese,31 Hispanic35 and South Asian32 popu-
lations, and in a study focusing on fasting glucose in an
African-American36 population, despite possible differ-
ences in linkage disequilibrium (LD) between marker and
causal variants in each population. Indeed, multiethnic
differences in regional LD help with refinement of associa-
tion signals and can distinguish causal variants from
correlatedmarkers.33,37 Furthermore, independent associa-
tion signals in the same gene (for example, KCNQ1) in
different ethnicities could be useful for pinpointing genes
that harbor causal mutations. Recent power analyses sug-
gest that large-scale multiethnic association studies might
have greater statistical power to detect causal alleles because
random genetic drift can elevate global risk variants to a
higher allele frequency in different populations.38
The 50K SNP Human CVD beadchip, or ITMAT-Broad-
CARe (IBC) array, captures genetic diversity across more
than 2,000 candidate gene regions related to cardiovas-
cular, inflammatory, andmetabolic phenotypes, and a large
portion of loci are captured with marker density equal to
or greater than that found by GWAS.39 SNPs were selected
on the basis of the International HapMap Consortium and
publically available resequencing data such as those from
the SeattleSNPs and National Institute of Environmental
Health Sciences (NIEHS) SNPs consortia. The focus was
on the inclusion of rare variants and variants with a
high likelihood of functionality. More than 5,000 SNPs
from 49 candidate genes (Table S1, available online) were
specifically selected on the basis of prior evidence of a
role in Mendelian forms of diabetes,40 diabetes patho-
physiology (including insulin signaling, endocrine path-
ways, and energy metabolism),41 linkage studies42 and
meta-analyses of T2D GWASs.18–22 GWAS efforts have, 2012
identified additional loci since the design of this array;
therefore, of the currently documented T2D loci, 21 candi-
date genes from eighteen loci and index SNPs from nine
additional T2D loci were included on the array. SNP
association for this array has been reported for a range of
phenotypes, including those involving coronary artery
disease,43,44 lipid traits,45 blood pressure,46,47 cardiomyop-
athy,48 blood traits49,50 and height.51
In this study we set out to discover novel T2D loci and
attempted to replicate, fine map, and detect independent
signals at known loci by combining T2D association results
across 39 studies genotyped on the IBC array. We per-
formed meta-analysis in individuals of European ancestry
(14,073 cases, 57,489 controls), African-American ancestry
(1,986 cases, 7,695 controls), Hispanic ancestry (592 cases,
1,410 controls), and Asian ancestry (767 cases, 3704 con-
trols). Using conditional analyses, we sought to identify
additional independent signals within associated loci.
Finally, we assessed the concordance of direction of effect
of new and established loci and a composite risk score of
known loci across ethnicities.Subjects and Methods
T2D Case and Control Definitions and Participating
Studies
For the IBC meta-analyses performed here, T2D cases were
defined on the basis of one of the six following criteria: (1) the
American Diabetes Association criteria;52 (2) fasting (8 hr or
longer fast) glucoseR 126 mg/dl (R7 mmol/liter); (3) 2 hr glucose
R 200 mg/dl (R11.1 mmol/liter) during an oral glucose tolerance
test (OGTT); (4) use of diabetes medications; (5) nonfasting plasma
glucose > 200 mg/dl, or (6) physician report or self-report of
physician-diagnosed diabetes. We selected cases for an age at diag-
nosis or age at examR25 years in order to minimize the inclusion
of cases with type 1 diabetes (T1D [MIM 222100]). Glutamic acid
decarboxylase (GAD) antibody status was not available in any IBC
cohorts, and so we could not definitively exclude subjects with
T1D or latent autoimmune diabetes of adults (LADA). Controls
within each study were individuals who, on the basis of the criteria
described above, were not classified as T2D cases in an exam when
they wereR25 years of age.
Clinical and genotype quality-control characteristics from the
39 datasets included in the IBC chip meta-analysis (these datasets
consisted of population-based cohorts, collections of cases and
controls for metabolic and cardiovascular phenotypes, and indi-
viduals collected for clinical trials) are described in Table S2.
All participating studies were required to obtain informed
consent for DNA analysis and to have received approval from local
institutional review boards. The individuals of European ancestry
sampled in the primary analysis were independent from the
subjects included in the eight component studies of the previously
reported DIAGRAM GWAS meta-analysis used for in silico replica-
tion.24 GAD antibody status was available for subjects from four
component GWASs of the DIAGRAM consortium, and T2D associ-
ation results for each component DIAGRAM study were obtained
for SNPs rs9273363 (HLA-DQB1 [MIM 604305]) and rs10770141
(TH/INS region [MIMs 191290 and 176730]) from the DIAGRAM
investigators.The AmeGenotyping and Quality Control
Genotyping in each component study of the IBC meta-analysis
was performed with the IBC array.39 SNPs were clustered into
genotypes with the Illumina Beadstudio software and subjected
to quality-control filters at the sample and SNP levels separately
within each cohort. Samples were excluded for individual call rates
<90%, gender mismatch, and duplicate discordance. SNPs
were removed for call rates <95% or Hardy-Weinberg equilibrium
p < 107 in controls from each cohort (regardless of ethnicity).
Because of the low-frequency SNPs included in the design and
the aim to capture low-frequency variants of large effect across
the large dataset, we filtered only on minor allele frequency
(MAF) < 0.005.
Statistical Analyses
Evaluation of Population Stratification
For the primary meta-analysis, only individuals of European
ancestry were included. Self-reported ethnicity was verified by
multidimensional scaling (MDS) analysis of identity-by-state
distances as implemented in PLINK; HapMap panels were in-
cluded as reference standards. After SNPs in LD (r2 > 0.3) were
pruned out, Eigenstrat was used for computing principal compo-
nents on the subset of nonexcluded individuals for use as covari-
ates in the regression analyses.53,54
Association Testing
We performed T2D association analysis in each study by using an
additive genetic model. Our primary association analysis included
adjustment for age, sex, body-mass index (BMI), study site(s), and
principal components (PCs) if population structure was evident.
The genomic control inflation factor, l, was calculated in each
case-control study and used for within-study correction before
meta-analysis. l ranged from 1.0 to 1.077. As the Look AHEAD
study55,56 was a case-only study, we merged this dataset with
4,124 randomly selected ARIC controls of European ancestry for
association analysis. After performing stringent quality control,
we found limited population structure between the two datasets
and a l of 1.04. ARIC individuals used for the Look AHEAD
(cases)/ARIC (controls) sample were not included in the ARIC
IBC association analysis reported here (1,278 ARIC cases and
2,600 independent ARIC controls). Notably, Look AHEAD partici-
pants were obese (with an average BMI of 36.05 5.9 kg/m2), and
ARIC controls selected for matching were not (average BMI of
27.7 5 5.2 kg/m2). Despite BMI adjustment, this discrepancy
could lead to T2D association signals arising from SNP associations
to BMI.
Meta-analyses within each ethnic group were performed by two
independent analysts who used a fixed-effect inverse-variance
approach in two different software packages: MANTEL and
METAL.33 After association tests in each ethnicity, a multiethnic
meta-analysis that included all available participants was per-
formed. Additionally, the direction of effect of lead SNPs from pre-
viously identified loci was evaluated for consistency in African-
Americans, Hispanics, and Asians.
Previous studies using the IBC array have used different signifi-
cance thresholds, from p< 13 105 to p< 13 106.43, 45 To calcu-
late an appropriate significance threshold, we used data from the
Candidate Gene Association Resource (CARe) IBC array studies57
and determined that after LD was accounted for, the effec-
tive number of independent tests was ~26,500 for African
Americans and i~20,500 for Europeans. This produces an experi-
mental or study-wide statistical threshold of p ¼ 1.9 3 106 and
p ¼ 2.4 3 106, respectively, if a false-positive rate of 5% is to berican Journal of Human Genetics 90, 410–425, March 9, 2012 413
maintained.Consistentwith thehypothesis-drivencandidategene
approach taken here, we have adopted these ‘‘array-wide’’ or study-
wide statistical thresholds for this study, but we also highlight loci
significantly associated at a more conventional genome-wide-
significant threshold of p < 5.0 3 108.
For confirmation of signals previously associated with T2D, we
selected the exact SNP from the most recent discovery study or
meta-analysis when possible. If the SNP was not present on the
array, we selected from the IBC array a SNP that was in highest
linkage disequilibrium with the previously identified SNP in the
HapMap CEU (Utah residents with northern and Western Euro-
pean ancestry from the CEPH collection) population (this SNP
was identified with the online tool SNAP). Selected SNPs and r2
to previously associated SNPs are shown in Table S1.
Conditional Analyses
Forty-six loci harboring nominally significant evidence for associ-
ation (p < 1.0 3 104) were examined for additional signals via
conditional analyses in PLINK.58 A term was added to the regres-
sion model so that the lead SNP was included as a covariate, and
SNPs within the same candidate gene, or5 200 kb if the candidate
gene region was <200 kb, were evaluated for significance. Condi-
tional analysis was performed in fifteen European and eight
African-American cohorts with individual-level genotype data.
We applied a locus-specific Bonferroni correction (i.e., correction
for SNPs tested within the same candidate gene or within 200 kb
if the candidate gene region was <200 kb) to determine the signif-
icance of independent signals within candidate genes genotyped
at each locus. Table S1 shows the number of SNPs (and therefore
tests) per locus on which the locus-wide significance level was
based.
Genetic-Risk-Score Analyses
In eight African-American, Asian, and Hispanic cohorts from the
CARe study, we generated a genetic-risk score of 27 T2D-associated
SNPs (26 previously established genome-wide-significant T2D-
associated SNPs and the index SNP from the GATAD2A signal
from this study) weighted by the log of the OR frommeta-analyses
of GWASs24,25 as described previously.59 We evaluated the contri-
bution of the weighted genetic risk score to T2D in logistic regres-
sion models adjusting for age, gender, BMI, and ten principal
components and compared the relativeORs across quartiles of risk.Results
Meta-Analysis of Samples of European Ancestry
We performed association testing for T2D status (tests
included 14,073 cases and 57,489 controls) and adjusted
for age, gender, BMI, and three or more PCs in 25 European
IBC studies. After a fixed-effects, inverse-variance meta-
analysis, independent SNPs at HLA-DQB1, SREBF1 (MIM
184756), GATAD2A/CILP2 (MIM 612419)/PBX4 (MIM
608127), BCL2 (MIM 151430), and 16 previously described
loci were significantly associated with T2D at study-wide
significance (p < 2.4 3 106), and SNPs at eight known
loci surpassed the traditional genome-wide-significance
threshold (p < 5.0 3 108; Tables 1 and 2; Figures S1A
and S1B).Of the study-wide significant loci, SNPs correlated
to the most significant SREBF1 polymorphism (r2> 0.85 in
HapMap CEU) have been reported previously in candidate-
gene analyses60,61 but not in large-scale genomic studies
with robust replication. Our sample-selection and study-414 The American Journal of Human Genetics 90, 410–425, March 9design strategies are validated by study-wide-significant
independent replication of 14 out of 29 previously reported
T2D-associated loci present on the IBC chip (Table 2) and
nominal association of 23/29 loci with a consistent direc-
tion of effect for all signals. For five T2D association signals
tagged by variants on the IBC array (these signals were in or
near RBMS1 [MIM 602310], CENTD2 [MIM 606646],
ZFAND6 [MIM 610183], HMGA2 [MIM 600698], or
HNF1A), overlapping samples fromfour component studies
(ARIC, CCCS, FHS, and KORA) were included in the initial
report,24 and therefore our results are not independent.
In order to confirm putative novel signals, we carried out
in silico follow-up analyses of 25 SNPs from previously
undescribed T2D-associated signals (p < 1.0 3 104) in a
meta-analysis of eight GWASs (n ¼ 8,130 cases and
38,987 controls of European ancestry) from the DIAGRAM
consortium.24 Combined meta-analyses of the discovery
and replication studies led to genome-wide-significant
signals at the GATAD2A/CILP2/PBX4 (p ¼ 5.7 3 109)
and HLA-DQB1 (p ¼ 1.1 3 108) loci; the signal at SREBF1
remained study-wide significant, and a signal at TH/INS
became study-wide significant (Table 1, Figures 1A–1D).
Furthermore, 12/18 additional SNPs displayed a direction
of effect consistent with our discovery dataset, suggesting
that additional loci might have weaker effects that
are undetectable as a result of limited statistical power
(Table S3). Lead or correlated SNPs for three signals with
p < 105 in the IBC meta-analysis at the BCL2, CDKN1B
(MIM 600778), and SLC39A4 (MIM 607059) loci were
not included in the DIAGRAM meta-analysis (Table S3),
and these signals, as well as our study-wide-significant
findings, will need independent follow-up in future studies
of European ancestry.
The HLA-DQB1 allele has previously been demonstrated
to exhibit a strong association with type 1 diabetes (odds
ratio [OR] > 5.4). To determine whether the association
signal observed at this locus was driven by cases with
LADA, we examined association of this SNP in DIAGRAM
component studies with and without exclusion of GAD-
antibody-positive cases. We observed a trend toward
more significant association of the SNP in meta-analysis
of studies including LADA than in the study set that
excluded LADA (Table S4), suggesting this signal might
indeed stem from a subset of cases with autoimmune dia-
betes misclassified as T2D; however, this difference was
not statistically significant (Phet ¼ 0.51). To explore
whether rs9273363 in HLA-DQB1 in fact represents
a T1D signal, we imputed classical HLA alleles in 10,636
cases and 38,063 controls from our IBC dataset by using
a reference set of 2,767 European individuals with four-
digit genotype data for HLA-A (MIM 142800), HLA-B
(MIM 142830), HLA-C (MIM 142840), HLA-DQA1 (MIM
146880), HLA-DQB1, HLA-DRB1 (MIM 142857), HLA-
DPA1 (MIM 142880), and HLA-DPB1 (MIM 142858).62
After imputation, we tested imputed classical HLA alleles
for association with T2D by using logistic regression
including age, sex, BMI, study site, and three PCs as, 2012
Table 1. Loci Associated with T2D in Individuals of European Ancestry
European-Ancestry IBC Meta-Analysisa DIAGRAM Meta-Analysisb Combined European Ancestry Meta-Analysisc
Chr NCBI 36 Position Candidate Gened SNP RA RAF IBC OR (95% CI) p % I2 OR (95% CI) p OR (95% CI) p Percent I2
SNPs with Study-wide Significance
19 19471596 GATAD2A rs3794991 T 0.08 1.14 (1.08–1.20) 8.95 3 107 25 1.11 (1.04–1.17) 1.55 3 103 1.12 (1.08–1.15) 5.70 3 109 22
17 17662182 SREBF1 rs4925115 A 0.38 1.09 (1.05–1.12) 2.04 3 107 0 1.04 (0.99–1.08) 1.01 3 101 1.07 (1.04–1.10) 2.62 3 107 0
11 2150416 TH/INS rs10770141 A 0.39 1.07 (1.04–1.11) 6.44 3 106 0 1.05 (1.00–1.10) 7.08 3 102 1.07 (1.04-1.10) 1.57 3 106 0
18 58996864 BCL2 rs12454712 T 0.63 1.08 (1.04–1.11) 2.29 3 106 21 - - - - -
SNPs with Borderline Significancee
11 49127350 FOLH1 rs16906158 C 0.09 1.13 (1.07–1.19) 8.75 3 106 32 1.07 (1.00–1.14) 5.17 3 102 1.10 (1.06–1.15) 2.57 3 106 32
3 172217793 SLC2A2 rs11924032 G 0.74 1.08 (1.04–1.12) 1.87 3 105 0 1.05 (1.00–1.10) 3.31 3 102 1.06 (1.04–1.10) 2.60 3 106 0
19 50864118 GIPR rs11671664 A 0.11 1.12 (1.07–1.18) 2.86 3 106 0 1.06 (0.98–1.14) 1.71 3 101 1.10 (1.06-1.15) 2.61 3 106 0
SNPs with Likely Association to LADA or Autoimmune Diabetes Componentf
6 32734250 HLA-DQB1 rs9273363 A 0.27 1.10 (1.06–1.14) 7.99 3 108 17 1.06 (1.01–1.10) 1.64 3 102 1.08 (1.05–1.11) 1.10 3 108 19
Abbreviations are as follows: Chr, chromosome; RA, risk allele; RAF, risk-allele frequency; OR, odds ratio; and CI confidence interval.
a14,073 cases and 57,489 controls.
b8,130 cases and 38,987 controls.
c22,203 cases and 94,476 controls.
dCandidate gene selected for testing on the array.
eIBC Study-wide significance ¼ p < 2.4 3 106.
fSee Tables S4 and S5.
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
9
0
,
4
1
0
–
4
2
5
,
M
a
rch
9
,
2
0
1
2
4
1
5
Table 2. Association Results for Known T2D Loci in Meta-Analysis of IBC Studies of European Ancestry
Chr Prev. Assoc. SNP Pos (NCBI 36) Candidate Gene Lead SNP on IBC array r2 to Prev. Assoc. SNP RA RAF IBC OR (95% CI) p I2 (%)
1 rs10923931 120,319,482 NOTCH2 T 0.10 1.06 (1.01–1.12) 3.23 3 102 21.0
1 120,239,407 NOTCH2 rs2641348 0.85 (rs10923931) G 0.11 1.06 (1.01–1.12) 1.95 3 102 16.0
2 rs780094 27,594,741 GCKR rs780094 0.93 (rs1260326) C 0.59 1.09 (1.05–1.12) 2.12 3 107 43.0
2 rs7578597 43,586,327 THADA rs7578597 T 0.90 1.16 (1.10–1.22) 2.91 3 107 34.4
2 rs7593730 160,879,700 RBMS1 rs6718526 0.83 (rs7593730) C 0.79 1.03 (0.99–1.07) 1.20 3 101 0
3 rs1801282 12,368,125 PPARG C 0.88 1.11 (1.10–1.16) 2.15 3 105 0
3 12,367,272 PPARG rs7649970 1 (rs1801282) C 0.88 1.11 (1.06–1.16) 7.87 3 106 0
3 rs4607103 64,686,944 ADAMTS9 C 0.74 1.05 (1.02–1.10) 4.11 3 103 0
64,676,186 ADAMTS9 rs9860730 0.69 (rs4607103) A 0.68 1.05 (1.02–1.09) 1.24 3 103 0
3 rs1470579 187,011,774 IGF2BP2 rs1470579 C 0.32 1.14 (1.10–1.18) 9.19 3 1016 8.8
4 rs10010131 6,343,816 WFS1 G 0.60 1.10 (1.01–1.20) 3.37 3 102 76.9
6,336,616 WFS1 rs4688985 0.58 (rs10010131) G 0.73 1.10 (1.05–1.14) 2.88 3 107 34.8
6 rs7754840 20,769,229 CDKAL1 C 0.32 1.16 (1.12–1.20) 4.58 3 1019 0
20,794,975 CDKAL1 rs9368222 0.63 (rs7754840) A 0.27 1.18 (1.14–1.22) 5.37 3 1021 0
7 rs10244051 15,030,358 DGKB-TMEM195 rs10244051 1 (rs2191349) G 0.54 1.04 (0.95–1.14) 4.02 3 101 55.3
7 rs864745 28,147,081 JAZF1 rs864745 0.97 (rs849134) T 0.50 1.11 (1.08–1.14) 2.22 3 109 31.3
7 rs4607517 44,202,193 GCK A 0.18 1.10 (0.98–1.23) 1.07 3 101 0
7 44,189,327 GCK rs1990458 0.18 (rs4607517) C 0.59 1.08 (1.04–1.11) 1.67 3 106 0
8 rs13266634 118,253,964 SLC30A8 rs13266634 C 0.70 1.11 (1.08–1.15) 2.49 3 109 29.5
9 rs10811661 22,124,094 CDKN2A/B rs10811661 T 0.82 1.19 (1.14–1.23) 4.83 3 1016 0
10 rs12779790 12,368,016 CDC123/CAMK1D rs12779790 G 0.18 1.07 (0.99–1.15) 7.28 3 102 4.7
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Table 2. Continued
Chr Prev. Assoc. SNP Pos (NCBI 36) Candidate Gene Lead SNP on IBC array r2 to Prev. Assoc. SNP RA RAF IBC OR (95% CI) p I2 (%)
10 rs5015480 94,455,539 HHEX/IDE rs5015480 C 0.60 1.12 (1.10–1.16) 2.68 3 1014 12.3
10 rs7903146 114,748,339 TCF7L2 rs7903146 T 0.30 1.44 (1.40–1.49) 1.21 3 10109 27.6
11 rs163184 2,803,645 KCNQ1 rs163184 G 0.48 1.08 (1.05–1.11) 6.08 3 107 0
11 rs2237892 2,796,327 KCNQ1 rs2237892 C 0.94 1.11 (0.92–1.37) 2.61 3 101 0
11 rs231362 2,648,047 KCNQ1 rs231362 G 0.52 1.08 (1.04–1.11) 5.90 3 106 3.8
11 rs5215 17,365,206 KCNJ11 rs5215 0.93 (rs5219) C 0.37 1.09 (1.06–1.13) 1.65 3 108 15.2
11 rs1552224 72,110,746 CENTD2 region rs613937 0.86 (rs1552224) A 0.81 1.08 (1.04–1.13) 1.17 3 104 0
11 rs10830963 92,348,358 MTNR1B rs10830963 G 0.30 1.05 (1.01–1.08) 8.07 3 103 21.0
11 rs2943634 226,776,324 IRS1 region rs2943634 0.82 (rs7578326) C 0.67 1.09 (1.05–1.12) 4.32 3 107 16.4
12 rs7961581 69,949,369 TSPAN8/LGR5 rs7961581 0.87 (rs4760790) G 0.71 1.06 (1.01–1.10) 1.57 3 102 0
12 64,569,867 HMGA2 rs17179453 0.57 (rs1531343) C 0.09 1.10 (1.05–1.16) 3.73 3 104 11.9
12 rs7957197 119,945,069 HNF1A rs12427353 0.88 (rs7957197) G 0.77 1.07 (1.03–1.12) 4.76 3 104 0
15 78,200,439 ZFAND6 rs2903265 0.71 (rs11634397) G 0.72 1.01 (0.98-1.05) 4.62 3 101 4.2
16 rs11642841 52,402,988 FTO rs11642841 A 0.41 1.06 (1.03–1.09) 1.78 3 104 14.8
17 rs4430796 33,172,153 HNF1B rs4430796 0.54 (rs757210) G 0.51 1.08 (1.05–1.12) 2.48 3 107 0
X rs5945326 152,553,116 DUSP9 rs5945326 A 0.77 1.09 (1.03–1.15) 2.53 3 103 0
The study included 14,073 cases and 57,489 controls. Abbreviations are as follows: Chr, chromosome; Prev. assoc., previously reported T2D-associated SNP; Pos, position; RA, risk allele; RAF, risk-allele frequency; OR, odds
ratio; and CI, confidence interval.
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Figure 1. Regional Plots for T2D Loci with Study-Wide-Significant Regions in IBC Meta-Analysis of Data from Individuals with
European Ancestry
Loci are shown as the lead SNP with a flanking region depicting the candidate gene and nearby genes included on the array. The purple
diamond represents the lead SNP in the IBCmeta-analysis, and the dots represent the surrounding SNPs; colors show the LD relationship
with the lead SNP on the basis of CEU HapMap II information. –log10 p values for association with T2D are shown for each SNP (left-
hand axis). Recombination rates in CEU HapMap II are shown in blue traces (right-hand axis).covariates. HLA-DQA1 was identified as the signal that was
the most significantly associated with T2D (HLA-
DQA1*03; p ¼ 2.8 3 107) and was closely followed by
HLA-DRB1 (HLA-DRB1*04; p ¼ 3.6 3 107; Table S5).
HLA-DQB1, HLA-DQA1, and HLA-DRB1 are major genetic
determinants of T1D,63–65 suggesting that the observed
association at HLA SNPs is an artifact caused by LADA
pollution of our cases. We repeated association analysis
conditioning on lead SNPs to identify other HLA-region
loci that were associated with T2D (both rs9273363 and418 The American Journal of Human Genetics 90, 410–425, March 9HLA-DQA1*03), but we found no additional association
signals.
Independent Signals at European T2D-Associated Loci
An advantage of our study over a GWAS is the inclusion of
rare missense SNPs at candidate loci. Such SNPs can help
identify independent T2D signals within genes at known
loci. We performed regional conditional-association
analyses by adjusting for lead SNPs at 46 signals with p <
104 in 10,636 cases and 38,063 controls of European, 2012
Table 3. Loci with Significant Evidence of Independent T2D Association Signals
Original Results Conditional Results
Gene SNP Chr.
NCBI36
Position
Effect
Allele
Freq.
IBC OR (95% CI) p OR (95% CI) p
r2 with
Lead SNP*
IBC European Ancestry (14,073 cases and 57,489 controls) (10,636 cases and 38,063 controls)
CDKN2A/B rs10811661 9 22,124,094 C 0.176 0.84
(0.81–0.88)
4.83 3 1016
rs10757282 9 22,123,984 C 0.433 1.04
(1.01–1.08)
2.23 3 102 1.14
(1.10–1.18)
2.41 3 1010 0.36
KCNQ1 rs163184 11 2,803,645 G 0.482 1.08
(1.05–1.11)
6.08 3 107
rs231362 11 2,648,047 A 0.477 0.93
(0.90–0.96)
5.90 3 106 0.90
(0.87–0.94)
1.98 3 107 0.025
PPARG rs17036160 3 12,367,272 T 0.121 0.90
(0.86–0.94)
7.87 3 106
rs1797912 3 12,445,239 A 0.636 1.06
(1.03–1.09)
5.48 3 105 1.08
(1.04–1.13)
6.15 3 105 0.053
THADA rs7578597 2 43,586,327 C 0.105 0.86
(0.82–0.91)
2.91 3 107
rs10200833 2 43,526,820 C 0.342 0.94
(0.91–0.98)
2.63 3 103 0.92
(0.88–0.96)
4.71 3 104 0.047
JAZF1 rs864745 7 28,147,081 C 0.502 0.90
(0.88–0.93)
2.22 3 109
rs12113122 7 28,147,769 G 0.051 1.55
(1.11–2.15)
5.13 3 102 1.42
(1.11–1.62)
1.21 3 102 0.002
IBC African Americans (1,986 cases and 7,695 controls) (1,867 cases and 7,580 controls)
HMGA2 rs9668162 12 64,555,049 G 0.222 1.26
(1.15–1.37)
2.41 3 107
rs1042725 12 64,644,614 T 0.38 1.08
(1.00–1.16)
3.76 3 102 1.14
(1.06–1.24)
0.00299 0.046ancestry. After Bonferroni correction for SNPs at the candi-
date gene locus, we found independent novel T2D signals
at the PPARG, THADA (MIM 611800), and JAZF1 (MIM
606246) loci and confirmed known secondary signals at
CDKN2A (MIM 600160)/CDKN2B (MIM 600431) and
KCNQ122,24 (Table 3). Additionally, Table S6 shows seven
locus-wide-significant signals in loci with primary associa-
tions of p < 2.5x104 in our study; these loci include GIPR,
which was recently associated with 2 hr glucose levels
during an OGTT.66
T2D Meta-Analysis in Multiethnic Populations
We next performed meta-analysis across IBC-array
T2D-association results independently in eight African-
American studies (1,986 cases, 7,695 controls), three
Hispanic-Latino studies (592 cases, 1,410 controls), and
three Asian studies (767 cases, 3704 controls). Although
these analyses were underpowered to detect novel loci at
genome-wide significance in these populations, we could
evaluate the contribution of known and identified T2D
loci to disease risk across ethnicities (Table S7).
In African Americans, study-wide significant association
was observed for SNPs within TCF7L2 (rs7903146 p ¼
5.1 3 1015) and within HMGA2 (rs9668162 p ¼ 2.4 3The Ame107; Table S7). HMGA2 encodes a transcriptional regu-
lator of IGF2BP2 (MIM 608289), a gene known to be asso-
ciated with T2D, and a T2D-associated signal ~43 kb
upstream of HMGA2 was recently described in a European
GWAS meta-analysis performed by the DIAGRAM con-
sortium (r2 ¼ 0.005 in CEU, r2 ¼ 0.35 in YRI [Yoruba in
Ibadan, Nigeria] to best European SNP;24). Because our
array coverage was limited to the HMGA2 region, we
cannot confirm whether the African-American signal ob-
served is independent from the previously reported
HMGA2 signal in Europeans; however, conditional anal-
ysis in African-American studies revealed two locus-wide-
significant associations (Table 3).
We further investigated whether the African-American
meta-analysis could refine localization of known T2D-
associated signals on the basis of differential LD or reveal
novel independent signals within genes known to be asso-
ciated with T2D. Three suggestive missense association
signals were identified for evaluation in future case-control
association studies. These signals included (1) rs34150427
in KCNQ1 (V648I/V521I; MAF 0.02; p ¼ 6 3 105), which
was absent in Europeans; (2) rs1801208 in WFS1 (R456H;
MAF 0.04; p ¼ 0.001); and (3) rs16889462 in SLC30A8
(MIM 611145), a SNP adjacent to known T2D-associatedrican Journal of Human Genetics 90, 410–425, March 9, 2012 419
Table 4. Prediction of Risk of T2D in CARe African-American,
Hispanic, and Asian Populations via aWeighted Genetic Score of 27
T2D Variants
African-American Hispanics Asians
Additive Risk per Allele
N (cases/controls) 1801/7253 297/874 109/529
OR (95% CI) 1.06
(1.04–1.08)
1.07
(1.03–1.12)
1.12
(1.04–1.22)
p 1.07 3 1010 0.0021 0.0047
Quartiles of Risk Alleles
Q1 OR (95% CI) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Q2 OR (95% CI) 1.13
(0.96–1.33)
1.06
(0.69–1.61)
1.77
(0.88–3.57)
p 0.14 0.802 0.114
Q3 OR (95% CI) 1.45
(1.24–1.70)
1.28
(0.85–1.94)
1.64
(0.81–3.33)
p 5.01 3 106 0.24 0.17
Q4 OR (95% CI) 1.53
(1.31–1.80)
1.69
(1.12–2.57)
2.63
(1.37–5.05)
p 1.90 3 107 0.013 0.0035
The 27 T2D variants on the IBC chip include 26 T2D-associated variants in
Table S1 and the lead
SNP in the GATAD2A region. p ¼ 0.34 for heterogeneity of allelic effects across
ethnic groups.SNP rs13266634, which alters codon R324 (MAF ¼ 0.10;
p ¼ 0.017) and was rare in Europeans (MAF ¼ 0.02,
p ¼ 0.28; Figures S2A–S2C).
In a multiethnic meta-analysis of all available IBC case-
control samples, 14 loci retained study-wide significance
(Table S7), and a variant in BCL2 attained genome-wide
significance (rs12454712T OR ¼ 1.09 [95% confidence
interval (CI): 1.05–1.11], p ¼ 2.1 3 108). Concordance
in direction of effect was observed for 27 of 40 T2D associ-
ation signals between Europeans and African Americans
(p ¼ 0.011). Thirty-two SNPs were concordant in direction
of effect betweenEuropeans andHispanics (p¼7.03105),
and 27 SNPs were concordant between Europeans and
Asians (p¼ 0.011). A total of 17 out of 40 SNPswere concor-
dant across all four ethnic groups. A combined genetic risk
score, comprising 26 previously described, robustly T2D-
associated variants (listed in Table S1) and the genome-
wide-significant GATAD2A-region signal discovered in
this study, demonstrated a significant per-allele risk effect
in African-American (OR ¼ 1.06 [95% CI: 1.04–1.08]; p <
1010), Hispanic (OR ¼ 1.07 [95% CI: 1.03–1.12]; p <
103), and Asian cohorts (OR ¼ 1.12 [95% CI: 1.04–1.22];
p< 103) from theCARe study (Table 4), suggesting overlap
of causal T2D risk alleles across multiple ethnic groups.Discussion
This study reports a large meta-analysis of T2D-candidate-
gene association studies and has identified three additional420 The American Journal of Human Genetics 90, 410–425, March 9diabetes-associated loci, verified known T2D-associated
loci, and uncoveredmultiple independent T2D association
signals, demonstrating the power of large collaborative
approaches to uncover genetic insights in T2D. Further-
more, we have evaluated the impact of established T2D
risk variants on risk of T2D in multiethnic populations.
Samples were assembled primarily through population-
based studies and clinical trials; only one study (Look
AHEAD) solely recruited T2D cases. As a validation of sam-
ples included in this study, 22 of 25 studies of European
ancestry showed the expected association of TCF7L2
SNPs at p < 0.05 in the expected direction (Table S8),
and 25 of 27 known T2D index SNPs or close proxies
were replicated with p < 0.05 as described. A particular
strength of our study as compared to other large-scale
meta-analyses of T2D is that all participating studies per-
formed association analyses adjusted for sex, age, and
BMI, reducing confounding effects.
We identified a novel diabetes-associated locus at
GATAD2A/CILP2/PBX4, included on the IBC array
because it was previously described as being associated
with lipid levels.39 GATAD2A rs3794991 is in strong LD
(r2 > 0.90 in HapMap CEU) with rs16996148 (near
CILP2/PBX4), previously associated with low-density lipo-
protein (LDL) cholesterol and triglycerides (TGs) in meta-
analysis of GWAS67 and in previous IBC studies of TG
levels.45 Interestingly, the LDL and TG-lowering allele
is associated with increased risk of T2D, reminiscent
of the contrasting effects on T2D and triglyceride levels
of the pleiotropic missense P446L SNP in GCKR.68
GATAD2A encodes the GATA zinc finger domain contain-
ing 2A, a transcriptional repressor that interacts with the
methyl-CpG-binding domain proteins MBD2 (MIM
603547) and MBD3 (MIM 603573). Methyl-CpG-binding
domain proteins mediate functional responses of methyl-
ated DNA. PBX4 encodes a homeodomain protein with
similarity to a transcription factor involved in transloca-
tions in pre-B cell leukemias, and CILP2 encodes cartilage
intermediate layer protein 2. Further studies are needed to
establish the genetic variants that contribute to diabetes
and lipid traits and to establish the causal mechanisms
at this locus.
T2D-associated SNPs at the second genome-wide sig-
nificant locus, the HLA-DQB1 region, have previously
been strongly associated with type 1 diabetes (T1D) as
one of four independent signals from the HLA region.65
This signal most likely represents association with LADA
in both the IBC array and DIAGRAM T2D datasets; among
most T2D studies, approximately 10% of ‘‘cases’’ are actu-
ally misdiagnosed individuals with LADA.69 An alternative
hypothesis is that T1D risk alleles confer a much weaker
risk to T2D.70 In this study, we show that the association
of HLA SNPs with T2D is most likely an artifact caused
by the inclusion of misdiagnosed individuals with LADA
in our study, as indicated both by the comparison of
DIAGRAM component studies with and without LADA
cases and fine mapping of the major signal in the HLA, 2012
region. If we assume an OR of 5.49 for the HLA signal in
the LADA cases,71 we estimate the percentage of LADA
cases in our total cases set to be 7.6%, consistent with
previous estimates.69
A second T1D risk allele (rs10770141, located in the
promoter region of tyrosine hydroxylase [TH] and 11 kb
upstream of the insulin (INS) gene) was study-wide signif-
icant, but interestingly, this T1D risk allele was protective
for T2D. Although located close to the insulin gene, this
SNP regulates expression of TH; the T2D risk allele in-
creases expression, and the T1D risk allele lowers expres-
sion.72,73 The signal is not correlated with a minisatellite
upstream of the insulin gene; this minisatellite has pre-
viously been inconsistently associated with risk of
T2D.74,75 Replication in independent cohorts will be
important for the validation of this finding, and functional
studies will be required to establish whether causal variants
at this locus indeed act antagonistically to contribute to
type 1 and type 2 diabetes. No significant association
with T2D was found for other SNPs that had genome-
wide-significant associations with T1D (Table S9).
The fourth signal resides in SREBF1, which encodes the
transcription factors sterol-regulatory-element-binding
protein (SREBP)-1a and -1c. Whereas SREBP1a is ubiqui-
tously expressed, SREBP1c is particularly expressed in
insulin-sensitive tissues such as liver and adipose. SREBP1a
and SREBP1c control lipid synthesis and glucose metabo-
lism by regulating the expression of key genes involved
in glucose, fatty acid, and triglyceride metabolism.76,77
Variants in SREBF1 have previously been shown to be asso-
ciatedwith T2D in several candidate-gene studies.60,61,78–80
All reported associated variants are in substantial LD with
our most significantly associated SNP, rs4925115 (1000
Genomes Pilot 1: r2¼ 0.81–0.89). However, thus far GWASs
have not detected SREBF1 as a T2D locus, perhaps because
most GWASs did not systematically adjust for the con-
founding factors of sex, age and BMI, and these adjust-
ments were demonstrated to be essential for detection of
this association in a previous study.60 Specifically, in the
DIAGRAM meta-analysis, most component studies did
not adjust for sex, age, and BMI, providing a likely explana-
tion as towhy the SREBF1 signalwas not strongly replicated
(Table 1).
T2D association signals that were close to study-wide
significance include compelling candidates previously
confirmed as associated with glycemic diabetes-related
traits; such candidates include MADD (MIM 603584) near
FOLH1 (MIM 600934),25 the glucose transporter 2 isoform
SLC2A2 (MIM 138160),25 and gastric inhibitory polypep-
tide receptor GIPR (MIM 137241).66 These suggestive find-
ings are consistent with the hypothesis that a large number
of common variants and genes with modest effects con-
tribute to the risk of T2D and that current studies are
underpowered to detect these effects. Indeed, despite the
large sample sizes assembled here, a limitation of our study
is that significant and borderline-significant associations
based on combined analysis of the European IBC andThe AmeDIAGRAM datasets will need additional independent repli-
cation and follow-up.
Multiethnic meta-analysis across all 39 studies identified
association of a common variant in BCL2 with T2D, an
anti-apoptotic protein that has not previously been impli-
cated in this disease. Meta-analysis of IBC array studies in
African Americans also identified study-wide-significant
association of independent alleles at HMGA2, suggesting
that this gene might be causal across different ethnicities.
Our observations that a genetic risk score of 27 variants
associates with a risk of T2D in African Americans, Asians,
and Hispanic populations is also consistent with the idea
that at least a subset of T2D causal risk alleles spans ethnic-
ities. The genetic risk score analysis confirms and extends
findings in a previous study by Waters et al.,34 who report
consistent association of 19 European T2D risk variants in
several racial and ethnic groups from the US. Notably, our
study included additional correction for population struc-
ture, which may contribute to the slightly reduced effect
sizes observed.
In addition to common variants, the IBC array was
selected to capture rare missense variants at select loci
that are not directly captured or imputable by conven-
tional GWASs. Robust association of an established
missense SNP in HNF1a (rs1800574) with MAF ¼ 0.029
(p ¼ 1.4 3 107 in samples of European ancestry;
Table S7)13 validates the platform’s ability to detect rare
variation that contributes to the risk of T2D. Although
no rare variants reached study-wide significance, several
follow-up candidate variants in known T2D loci were iden-
tified in African Americans.
In conclusion, this large-scale gene-centric meta-analysis
of 39 multiethnic T2D association studies identified three
European T2D risk loci (GATAD2A/CILP2/PBX4, previously
known to have protective effects on lipids; TH/INS, previ-
ously known to have protective effects on T1D, and
SREBF1), one African-American T2D risk locus (HMGA2),
and one multiethnic risk locus (BCL2) and confirmed
that a genetic score of T2D risk alleles influence risk
of T2D in multiethnic populations including African-
Americans, Hispanics, and Asians. Thus, well-powered,
multiethnic GWASs of T2D should lead to the discovery
of additional diabetes-associated genes relevant tomultiple
ethnic groups.Supplemental Data
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